Bio Techne Corp Stock Performance
| TECH Stock | USD 59.65 0.84 1.43% |
The firm shows a Beta (market volatility) of 1.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Techne will likely underperform. At this point, Bio Techne Corp has a negative expected return of -0.0375%. Please make sure to confirm Bio Techne's expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Bio Techne Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bio Techne Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental indicators, Bio Techne is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return 1.43 | Five Day Return 0.86 | Ten Year Return 170.4 | All Time Return 54.4 K |
Forward Dividend Yield 0.0054 | Payout Ratio | Last Split Factor 4:1 | Forward Dividend Rate 0.32 | Dividend Date 2025-11-28 |
1 | Acquisition by Baumgartner Robert V of 3777 shares of Bio Techne at 60.96 subject to Rule 16b-3 | 10/30/2025 |
2 | How AI Spatial Biology Advances from SITC 2025 Could Shape Bio-Techne Revenue Drivers | 11/05/2025 |
3 | Is Bio-Techne Corporation a High-Quality Growth-Oriented Compounder Within The Healthcare Sector | 11/13/2025 |
| Bio Techne dividend paid on 28th of November 2025 | 11/28/2025 |
5 | 95,046 Shares in Bio-Techne Corp TECH Purchased by Capital Fund Management S.A. | 12/02/2025 |
6 | Cresset Asset Management LLC Boosts Holdings in Bio-Techne Corp TECH - MarketBeat | 12/05/2025 |
7 | Q3 Earnings Outperformers Agilent And The Rest Of The Research Tools Consumables Stocks | 12/10/2025 |
8 | Osterweis Capital Management Inc. Has 7.70 Million Stake in Bio-Techne Corp TECH | 12/12/2025 |
9 | Bio-Techne Stock Rating Lowered by Zacks Research | 12/19/2025 |
10 | Enanta Pharmaceuticals Surges 5.9 percent Is This an Indication of Further Gains | 12/22/2025 |
11 | Liquidity Mapping Around Price Events - Stock Traders Daily | 12/29/2025 |
| Begin Period Cash Flow | 151.8 M | |
| Total Cashflows From Investing Activities | -35.2 M |
Bio Techne Relative Risk vs. Return Landscape
If you would invest 6,184 in Bio Techne Corp on October 4, 2025 and sell it today you would lose (219.00) from holding Bio Techne Corp or give up 3.54% of portfolio value over 90 days. Bio Techne Corp is currently does not generate positive expected returns and assumes 2.0051% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bio Techne Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Techne's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Techne Corp, and traders can use it to determine the average amount a Bio Techne's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0187
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TECH |
Based on monthly moving average Bio Techne is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Techne by adding Bio Techne to a well-diversified portfolio.
Bio Techne Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Techne, and Bio Techne fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.038 | ||||
| Return On Asset | 0.0625 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 9.41 B | ||||
| Shares Outstanding | 155.81 M | ||||
| Price To Earning | 74.38 X | ||||
| Price To Book | 4.66 X | ||||
| Price To Sales | 7.53 X | ||||
| Revenue | 1.22 B | ||||
| Gross Profit | 813.2 M | ||||
| EBITDA | 216.88 M | ||||
| Net Income | 73.4 M | ||||
| Cash And Equivalents | 247.03 M | ||||
| Cash Per Share | 6.30 X | ||||
| Total Debt | 444.06 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.44 X | ||||
| Book Value Per Share | 12.62 X | ||||
| Cash Flow From Operations | 287.56 M | ||||
| Earnings Per Share | 0.49 X | ||||
| Market Capitalization | 9.16 B | ||||
| Total Asset | 2.56 B | ||||
| Retained Earnings | 1.07 B | ||||
| Working Capital | 432.45 M | ||||
| Current Asset | 253.89 M | ||||
| Current Liabilities | 54.15 M | ||||
About Bio Techne Performance
By evaluating Bio Techne's fundamental ratios, stakeholders can gain valuable insights into Bio Techne's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio Techne has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio Techne has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 144.94 | 86.64 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.05 | 0.05 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.04 | 0.04 |
Things to note about Bio Techne Corp performance evaluation
Checking the ongoing alerts about Bio Techne for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Techne Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio Techne Corp generated a negative expected return over the last 90 days | |
| Over 100.0% of the company shares are owned by institutional investors | |
| On 28th of November 2025 Bio Techne paid $ 0.08 per share dividend to its current shareholders | |
| Latest headline from news.google.com: Liquidity Mapping Around Price Events - Stock Traders Daily |
- Analyzing Bio Techne's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Techne's stock is overvalued or undervalued compared to its peers.
- Examining Bio Techne's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Techne's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Techne's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Techne's stock. These opinions can provide insight into Bio Techne's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |